Table 1.

Selected trials incorporating TKIs in the initial therapy of Ph+ ALL

ReferenceNAge, median [range]RegimenCMR rate, %Allo-HCT rate, %RFS rate, %OS rate, %
Imatinib
 458048 [15-63]Intensive chemotherapy50 (day 63)4976 (1 y)
 392969 [61-83]Corticosteroids448 (1 y)74 (1 y)
 465945 [20-66]Intensive chemotherapy7239 (5 y)38 (5 y)
 916942 [16-64]Intensive chemotherapy7250 (4 y)38 (4 y)
 575451 [17-84]Intensive chemotherapy45 (overall)3043 (5 y)43 (5 y)
 1513345 [21-59]Intensive chemotherapy23 (2 cycles)6546 (5 y)
13549 [18-59]Low-intensity chemotherapy29 (2 cycles)6246 (5 y)
 373445 [24-57]Intensive chemotherapy4446 (5 y)51 (5 y)
 259210 [1.3-21]Intensive chemotherapy70 (5 y)
Dasatinib
 195354 [24-77]Corticosteroids15 (day 85)4222 (20 mo)31 (20 mo)
 477255 [21-80]Intensive chemotherapy65 (overall)1744 (5 y)46 (5 y)
 169744 [20-60]Intensive chemotherapy4262 (3 y)69 (3 y)
 407169 [55-83]Low-intensity chemotherapy24 (consolidation)1028 (5 y)36 (5 y)
 266010.2* [1.5-27.6]Intensive chemotherapy3260 (5 y)86 (5 y)
Nilotinib
 319047 [17-71]Intensive chemotherapy77 (3 mo)6372 (2 y)72 (2 y)
Ponatinib
 173751 [27-75]Intensive chemotherapy78 (overall)2480 (2 y)
 414468 [27-85]Corticosteroids61 (evaluable; 6 mo)87.5 (1 y)
  • CMR, complete molecular remission; OS, overall survival; RFS, relapse-free survival.

  • * Mean value provided.

  • Event-free survival provided.